Gilead Sciences vs Viatris
GILD and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GILD and VTRS compare
Gilead Sciences is the larger company, worth 9.7 times as much as Viatris ($212B against $21.9B).
Gilead Sciences grew revenue faster over the last twelve months (5.5% versus 4.4% for Viatris).
Both pay dividends: Gilead Sciences yields 1.9% and Viatris 2.5%.
Gilead Sciences scores higher on the StockData Score (11 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GILD | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | $212B | $21.9B |
| Share price | $170.68 | $19.04 |
| Change, 1 year | 44.0% | 85.3% |
| Change, 5 years | 157% | 38.6% |
| Beta (5Y) | 0.44 | 0.87 |
| Employees | 17K | 30K |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 3 (better) | 1 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/S | 6.9× | 1.5× (better) |
| P/B | 17.9× | – |
| EV/EBITDA | – | 12.6× |
| P/FCF | 16.4× | 11.2× (better) |
| FCF yield | 6.1% | 8.9% (better) |
| Fair value | $83.31 | $20.87 |
| Margin of safety | −105% | 8.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.5% (better) | 4.4% |
| Revenue growth, 5Y average | 3.6% | 3.7% (better) |
| Net income growth (TTM) | −151% | – |
| EPS growth (TTM) | −154% | – |
| EPS growth, 5Y average | 132% | – |
| Profitability | ||
| Gross margin | 79.6% (better) | 34.8% |
| Operating margin | −8.2% | −0.59% (better) |
| Net margin | −10.6% | – |
| FCF margin | 42.5% (better) | 13.3% |
| Return on equity | −20.6% | – |
| Return on invested capital | −5.3% | – |
| Financial health | ||
| Debt / equity | 2.22 | – |
| Net debt / EBITDA | – | 4.59 |
| Interest coverage | −2.5× | −0.2× (better) |
| Current ratio | 1.27 | 1.58 (better) |
| Altman Z-score | 3.96 (better) | 1.16 |
| Piotroski F-score | 8 | – |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | 2.5% (better) |
| Years of dividend growth | 11 (better) | 0 |
| Dividend growth, 5Y average | 3.0% | – |
| Buyback yield | 0.54% | 1.4% (better) |
| Shareholder yield | 2.4% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 89.9% | 91.5% |
| Held by insiders | 0.10% | 0.36% |
| Insider net buying, 12 months | −$83.5M | −$1.1M (better) |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 1.8% | 3.7% |
Go deeper
- GILD stock overview
- GILD income statement
- GILD valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.